Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant fruquintinib + toripalimab + short-course radiotherapy for locally advanced rectal cancer
ChiCTR2200063242Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and toripalimab in rectal cancer and rectal adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoints: Pathological complete response rate, 1-year disease-free survival rate and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
fruquintinibtoripalimab
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200063242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063242.